Monopar to Present at Roth Inaugural Healthcare Opportunities Conference

WILMETTE, Ill., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will present at the Roth Inaugural Healthcare Opportunities Conference.

Presentation Details:

Date: October 6, 2022Time: 12:00 p.m. (ET)Location: The Yale Club, New York City, New York

https://www.roth.com/conferences/upcoming-conferences

About Monopar Therapeutics Inc.

Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of Validive® for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin for the treatment of advanced soft tissue sarcoma; a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19; and an early-stage camsirubicin analog, MNPR-202, for various cancers. For more information, visit: www.monopartx.com.

CONTACT:  

Monopar Therapeutics Inc. Investor Relations   Kim R. Tsuchimoto   Chief Financial Officer   [email protected]

Follow Monopar on social media for updates:  Twitter: @MonoparTx  LinkedIn: Monopar Therapeutics

 

Source: Monopar Therapeutics Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Monopar Therapeutics (MNPR) PT Raised to $133 at BTIG
• MoonRush Launches Social Trading App Combining On-Chain Market Discovery and AI-Powered Risk Protection
• New Listing Buzz Explodes as ADA and DOGE Bleed While Pepeto Storms Toward Its Debut